---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-22-000199"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:37:19.123247+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q3 cash $421.7M, ZN-c3 dose optimization extends USC trial; Cyclin E biomarker strategy set

## Summary
- Cash $421.7M as of Sep 30, 2022; runway into Q1 2025.
- R&D expenses $42.2M (down 22% YoY); G&A $12.0M (up 35% YoY).
- ZN-c3 dose optimization extends USC trial timeline; update expected H1 2023.
- Cyclin E amplification/overexpression selected as biomarker for ZN-c3 monotherapy in ovarian cancer.
- Appointed new CMO (Carrie Brownstein), CSO (Kevin Bunker), CTO (Mark Lackner); added board member Jan Skvarka.

## SEC filing metadata
- accession: 0001725160-22-000199
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/0001725160-22-000199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/zntl-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-22-000199
- JSON: https://secwatch.observer/filing/0001725160-22-000199.json
- Plain text: https://secwatch.observer/filing/0001725160-22-000199.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/0001725160-22-000199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.